Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 214

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 214
---
 March 31, 2025 and December 31, 2024; 123,697 shares and 125,450 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively124 125 Additional paid-in capital1,532,835 1,504,671 Accumulated other comprehensive loss(2,644)(4,722)Accumulated deficit(999,374)(903,275)Total stockholders’ equity530,941 596,799 Total liabilities and stockholders’ equity$945,928 $986,256 

See accompanying notes.

4

Table of Contents

Dynavax Technologies Corporation 

Condensed Consolidated Statements of Operations 

(In thousands, except per share amounts) 

(Unaudited) 

Three Months Ended March 31,20252024Revenues:    Product revenue, net$64,959 $47,845 Other revenue3,205 2,945 Total revenues68,164 50,790 Operating expenses:    Cost of sales - product13,769 10,966 Research and development19,377 13,528 Selling, general and administrative47,678 44,065 Bad debt expense10,970 — Total operating expenses91,794 68,559 Loss from operations(23,630)(17,769)Other income (expense):    Interest income7,739 9,468 Interest expense(1,692)(1,695)Sublease income (expense) (Note 5)2,226 (1,602)Loss on debt extinguishment(82,095)— Other (loss) income(423)101 Net loss before income taxes(97,875)(11,497)Benefit from income taxes1,776 2,776 Net loss$(96,099)$(8,721)Net loss per share attributable to common stockholders    Basic$(0.77)$(0.07)Diluted$(0.77)$(0.07)Weighted-average shares used in computing net loss per share attributable to common stockholders:    Basic124,871 130,200 Diluted124,871 130,200 

See accompanying notes.

5

Table of Contents

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)

 Three Months Ended March 31, 20252024Net loss$(